Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 0.7969 0.02 (2.57%) Market Cap: 203.80 Mil Enterprise Value: 36.36 Mil PE Ratio: 0 PB Ratio: 2.11 GF Score: 62/100

Adaptimmune Therapeutics PLC Strategic Collaboration with Genentech Inc Presentation Transcript

Sep 09, 2021 / 12:00PM GMT
Release Date Price: $6.21 (-0.64%)
Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director

Presentation
Sep 09, 2021 / 12:00PM GMT

=====================
Corporate Participants
=====================
* Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director
* Helen Katrina Tayton-Martin
Adaptimmune Therapeutics plc - Co-Founder & Chief Business Officer
* Joanna Brewer
Adaptimmune Therapeutics plc - SVP of Allogeneic Research
* William C. Bertrand
Adaptimmune Therapeutics plc - COO

=====================
-

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot